CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 248 enrolled
Drug / intervention
Glycopyrronium MDI +2 moredrug
Likely dose
Serevent Diskus 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02433834
NCT02433834Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent® Diskus® in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Pearl Therapeutics, Inc.·interventional·Posted May 5, 2015·Updated Jul 2, 2017

In Brief

A Phase 2 clinical trial evaluating Glycopyrronium MDI, Serevent Diskus 50 μg, and 1 other intervention for Asthma. Completed, enrolled 248 participants across 43 sites.

Detailed Summary

A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001) Relative to Placebo MDI and Open-Label Serevent Diskus in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 5, 2015
Enrollment StartMay 27, 2015
Primary CompletionMar 26, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.2 years ago

Interventions

Glycopyrronium MDIdrug

GP MDI

Serevent Diskus 50 μgdrug

Placebodrug